Early PSA Response by 6 Months is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial

Early PSA response has been found to be prognostic of outcome in metastatic hormone sensitive prostate cancer (mHSPC). We performed a secondary analysis of TITAN trial to determine if early PSA response was predictive of treatment efficacy in mHSPC patients.